By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Sigma-Aldrich today reported 5 percent revenue growth on the strength of its fine chemicals business. Excluding the effect of foreign currency exchange rates, its revenues were up 7 percent.

The St. Louis-based research products and chemicals firm brought in total revenues of $563 million for the three-month period ended Sept. 30, compared with $534 million for Q3 2009. Analysts, on average, had expected sales of $542.3 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.